Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Interest Expenses (2022 - 2025)

Atara Biotherapeutics' Interest Expenses history spans 4 years, with the latest figure at $894000.0 for Q4 2025.

  • For Q4 2025, Interest Expenses fell 12.09% year-over-year to $894000.0; the TTM value through Dec 2025 reached $3.8 million, down 17.83%, while the annual FY2025 figure was $3.8 million, 17.83% down from the prior year.
  • Interest Expenses reached $894000.0 in Q4 2025 per ATRA's latest filing, down from $909000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.4 million in Q3 2023 to a low of $4000.0 in Q1 2022.
  • Average Interest Expenses over 4 years is $879062.5, with a median of $1.0 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: skyrocketed 33300.0% in 2023, then decreased 23.16% in 2025.
  • A 4-year view of Interest Expenses shows it stood at $117000.0 in 2022, then surged by 905.13% to $1.2 million in 2023, then dropped by 13.52% to $1.0 million in 2024, then fell by 12.09% to $894000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Interest Expenses are $894000.0 (Q4 2025), $909000.0 (Q3 2025), and $972000.0 (Q2 2025).